[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-mineral-and-bone-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-mineral-and-bone-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,82,109,137,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641620","phase-2-reducing-inflammation-to-improve-vascular-and-bone-outcomes-with-low-dose-colchicine-in-ckd-100641620",false,"NCT07654231","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD","Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)","RESOLVE-CKD","Inclusion Criteria:\n\n* Men and women aged 18-\\\u003C70 years of all race\u002Fethnicity groups\n* CKD stage 3 (estimated glomerular filtration rate (eGFR) \\>30 to 59 ml\u002Fmin\u002F1.73m2)\n* Urine albumin-to-creatinine ratio (uACR) ≥ 200 mg\u002Fg\n* Cardiac artery calcification (CAC) Agatston score ≥30\n* Hypertension, diabetes, dyslipidemia, or established atherosclerotic cardiovascular disease (ASCVD) (coronary artery disease (CAD), ischemic stroke, and peripheral artery disease), defined by self-report, ICD-10 codes, or the use of medications for these conditions.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Current Colchicine therapy\n* Hepatic disease\n* Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.\n* Immunosuppression\n* Current use of chemotherapy drugs or active cancer\n* Pregnancy\u002Fbreastfeeding\n* Hospitalized within the past 6 months\n* Allergic\u002Fintolerance to colchicine\n* Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir\u002Fritonavir, Saquinavir, Nelfinavir)\n* Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)\n* Human immunodeficiency virus (HIV) infection\n* Gout attack ≥ 1 time per year\n* Severe anemia (hemoglobin \\\u003C 8 g\u002Fdl for women and \\\u003C 9 g\u002Fdl for men)\n* eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2\n* uACR \\\u003C200 mg\u002Fg\n* White blood cell count (WBC) \\\u003C3.0 x109\u002FL\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 x Upper Limit of Normal (ULN)\n* Total bilirubin \\>2 x ULN\n* Glucose \\>300mg\u002Fdl\n* Uses nicotine products or other recreational drugs\n* Unable to read or speak English\n* Participant in other conflict clinical trial,\n* Unable to complete the study measurements\n* Unable to undergo to computed tomography (CT) or dual-energy X-ray absorptiometry (DXA) scans\n* Unsafe to participate in this study per investigator's judgement.","ALL","18 Years","69 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The overall objective of this pilot randomized clinical trial is to determine whether low-dose Colchicine (LoDoCo) improves vascular disease including vascular calcification, peripheral arterial disease (PAD), and chronic kidney disease-mineral and bone disorder (CKD-MBD) biomarkers in patients with chronic kidney disease (CKD) stage 3 over a 12-month intervention period, compared with usual care.\n\nSuccessful completion of this study will generate critical preliminary data to support a larger clinical trial aimed at evaluating inflammation-targeted therapies to mitigate CKD-MBD, including vascular calcification and related PAD, as well as osteoporosis, ultimately reducing cardiovascular events and mortality in patients with CKD. Additionally, this work has the potential to redefine the diagnostic framework for CKD-MBD.",[28,29,30,31,32,33],"Chronic Kidney Disease Mineral and Bone Disorder","Hypertension","Diabetes","Dyslipidemia","Atherosclerotic Cardiovascular Disease (ASCVD)","Chronic Kidney Disease (Stage 3)",[35,36,37,38],"Chronic Kidney Disease","CVD","vascular calcification","Colchicine","NOT_YET_RECRUITING","2026-06-17",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":22},"2026-07-01",{"date":47,"type":22},"2027-12-31",{"name":49,"class":50},"University of Texas Southwestern Medical Center","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":51},"100621309","phosphate-assessment-in-chronic-kidney-disease-patients-study-100621309","NCT07368946","Phosphate Assessment in Chronic Kidney Disease Patients Study","A Pilot Feeding Study to Assess Phosphate Overload in Patients With Chronic Kidney Disease","PACK","Inclusion Criteria:\n\n* Men or women aged 18 years or older, of any race\u002Fethnicity\n* Women must either be post-menopausal or have no monthly menstrual cycle\n* Estimated total daily energy expenditure (TDEE) of 1700 - 2700 calories\n* eGFR \\>15 ml\u002Fmin\u002F1.73m2 - \\\u003C 60 ml\u002Fmin\u002F1.73m2 for the CKD group (CKD Stage 3 or Stage 4)\n* eGFR ≥ 60 ml\u002Fmin\u002F1.73m2 and negative urine protein on dipstick test for the non-CKD group\n* English speaking\n\nExclusion Criteria:\n\n* Pregnant, currently breastfeeding, or \\\u003C3 months postpartum\n* Current dialysis or kidney transplant patient\n* Current use of insulin or chemotherapy drugs\n* Smokes cigarettes or uses e-cigarettes (vapes)\n* Uses nicotine products or other recreational drugs\n* Medical history of stroke or myocardial infarction (MI)\n* Medical history of conditions that can affect phosphate metabolism (i.e., uncontrolled thyroid disorder, parathyroid disorder, or gastrointestinal malabsorption disorders \\[Crohn's, ulcerative colitis, and celiac disease\\], cirrhosis)\n* Current use of certain medications that directly alter phosphate levels (i.e., phosphate binders; phosphate supplements, irregular use of iron)\n* Regular use of laxatives\n* Hypo- or hyperphosphatemia (serum phosphate \\\u003C 2.5 or \\> 4.6 mg\u002Fdl)\n* Hypo- or hypercalcemia (serum calcium \\\u003C 8.4 or \\> 10.7 mg\u002Fdl)\n* Severe anemia (hemoglobin \\\u003C 8 g\u002Fdl for women and \\\u003C 9 g\u002Fdl for men)\n* Severe hyperglycemia (serum blood glucose \\> 300 mg\u002Fdl)\n* Body weight less than \\\u003C110 lbs (due to risk for phlebotomy-induced anemia)\n* Received a blood transfusion in the last four months\n* Extreme hypertension as demonstrated by a blood pressure \\> 180\u002F120 as the average of 3 blood pressures taken during the screening\u002Fbaseline, or extremely low blood pressure \\\u003C 80\u002F50\n* Unwilling or unable to eat study meals\n* Lack of access to a functional refrigerator or freezer\n* Lack of access to a microwave or conventional oven\n* On low potassium diet\n* On low phosphate diet\n* Specific dietary restrictions (i.e. vegetarian, vegan, ketogenic, etc.)\n* Food allergies including but not limited to milk, egg, soy, nuts, shellfish, and wheat or gluten\n* Allergic to sodium phosphate\n* Unable or unwilling to complete urinary sample collection or food diaries\n* Unable or unwilling to provide informed consent\n* Unable to read or speak English\n* Participant in other conflict clinical trial\n* Unable to complete the study measurements\n* Unsafe to participate in this study per investigator's judgement",true,{"count":21,"type":22},[63],"NA","The proposed pilot feeding study aims to explore novel pathways in phosphate metabolism and identify new biomarkers, as well as to develop a compound index for assessing phosphate overload with high validity and reliability.\n\nInvestigators will address the following specific aims: 1). To explore novel pathways of phosphate metabolism and assess the influence of CKD status on these metabolic pathways. 2). To identify novel biomarkers for phosphate overload that reflect changes in dietary phosphorus intake. 3). To develop a compound phosphate overload index that measures dietary phosphorus intake with high validity and reliability.\n\nThis study will provide novel insights into phosphate metabolism and the assessment of phosphate overload in CKD patients. This investigation aims to provide preliminary data to further studies for the development of reliable biomarkers in CKD patients, which could contribute significantly to early interventions and improve health outcomes.",[66,28],"Chronic Kidney Disease (Stage 3-4)",[68,69,70,71,72],"chronic kidney disease","study diet","feeding study","pilot","oral phosphate feeding","RECRUITING","2026-01-26",{"date":76,"type":43},"2026-01-28",{"date":78,"type":43},"2025-05-09",{"date":80,"type":22},"2026-12-31",{"name":49,"class":50},{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":51},"100606105","the-effect-of-regulation-of-parathyroid-hormone-in-patients-with-chronic-kidney-disease-to-investigate-the-change-in-bone-mineral-density-100606105","NCT07171216","The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density","The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density (Biskjoldbruskkirtelhormon og knogletæthed Hos Patienter Med Kronisk Nyresygdom)","REPAIR-CKD","Inclusion Criteria:\n\n1. ≥50 years of age at screening\n2. CKD G4-5nonD (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2) based on local laboratory assessment of serum creatinine and eGFR estimated by the CKD-EPI formula)\n3. Plasma PTH \\> upper normal limit of local laboratory reference range (\\> 8,5µmol\u002FL) and\u002For treated with active vitamin D (Alphacalcidol) or calcimetics (Cinacalcet) initially\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Patients who have received a kidney transplant\n2. Patients receiving treatment with specific anti-osteoporosis medication (denosumab\u002Fbisphosphonates) (because of the profound effect on calcium\u002Fphosphate fluxes and BMD)","50 Years",{"count":92,"type":22},70,[63],"The prevalence of chronic kidney disease (CKD) in the adult population is estimated to 10%. CKD increases risk of bone fractures, cardiovascular disease and death. The main role of parathyroid hormone (PTH) is to regulate mineral metabolism, including the calcium and phosphate homeostasis. PTH increases as the kidney function declines, and at end stage kidney disease almost all patients have disturbances in the mineral metabolism. Decreasing bone mineral density is associated with risk of fracture, both in background population and in patients with CKD.\n\nFor decades, treatment with activated vitamin D, phosphate binders, and calcium supplements has been used for patients with chronic kidney disease and elevated parathyroid hormone, but treatment targets have varied greatly over the years, reflecting the lack of randomized clinical trials with clinical important end points.\n\nThe purpose of The REPAIR-CKD trial is to determine if treatment of hyperparathyroidism improves the bone mineral density in patients with chronic kidney disease.\n\nDuring this trial it will also be evaluated if it is feasible to obtain a difference in PTH levels when targeting two different levels of PTH.\n\nFurther this trial will explore if a difference in PTH influences on arterial stiffness, muscle mass, muscle function, bone histology and health related quality of life.",[28],[97,68,98,99],"parathyroid hormone","randomized clinical trial","Activated vitamin D","2026-01-05",{"date":102,"type":43},"2026-01-06",{"date":104,"type":43},"2025-11-20",{"date":106,"type":22},"2027-09-01",{"name":108,"class":50},"Herlev Hospital",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100607784","the-cph-mbd-cohort-100607784","NCT07193056","The CPH-MBD Cohort","Chronic Kidney Disease -Mineral and Bone Disorder, The CPH-MBD Cohort","Inclusion Criteria:\n\n* Age ≥18 years\n* CKD stage 4-5nonD (eGFR ≤ 29 ml\u002Fmin) according to KDIGO (Kidney Disease Improving Global Outcome) definition\n\nExclusion Criteria:\n\n* None",{"count":117,"type":22},1000,"25 Years","OBSERVATIONAL","Persons with chronic kidney disease (CKD) have a 3-fold increased risk of bone fracture and a 10-fold increased risk of cardiovascular disease than the general population. These increased risks are related to the disturbances in the mineral metabolism, and this clinical entity is termed Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD).\n\nThe overall aim of the present project is to explore factors that may predict or associate with the development of bone and cardiovascular disease in patients with CKD and hopefully provide insight into underlying mechanisms and pathophysiological pathways for future treatment and prevention.\n\nIn a sub study investigators aim to explore the calcium and phosphate balance in patients with CKD and describe how these associate with each other as well as with kidney function (eGFR).",[28,122,123],"Chronic Kidney Disease (CKD)","Bone Markers",[125,97,126,127,128],"bone markers","fracture risk","bone turnover","dietary assessment","2025-12-24",{"date":131,"type":43},"2025-12-31",{"date":133,"type":22},"2025-12",{"date":135,"type":22},"2055-01",{"name":108,"class":50},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":166},"100402619","phase-4-treatment-of-adynamic-bone-disorder-with-parathyroid-hormone-in-chronic-kidney-disease-100402619","NCT04522622","Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease","Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Patients With Chronic Kidney Disease","Inclusion Criteria:\n\n* Age ≥18 years\n* CKD stage 4-5D (eGFR ≤29 ml\u002Fmin) according to Kidney Disease Improving Global Outcomes(KDIGO) definition\n* DXA scan with a T-score at the total hip, femoral neck or lumbar spine (L1-4) ≤-2 (or Z-score ≤-2) in a minimum of 2 vertebraes (for patients with active oral prednisolone treatment ≥ 5 mg\u002Fday for minimum 3 months the T-score or Z-score limit i \\\u003C -1) and\u002For former fragility fracture (vertebral, hip, for- or upper arm, ankle) assessed with VFA or x-ray of the columna\n* Patients with expected adynamic bone disorder, based on BSAP≤21 µg\u002Fl or biopsy-verified low bone turnover\n\nExclusion Criteria:\n\n* Hypercalcemia defined as sustained ionized calcium \\>1.35 mmol\u002Fl\n* Previous fracture withon the last 6 months \\*Patients may be rescreened after the 6 months\n* Previous calciphylaxis\n* Thyroid disturbances not adequately treated based on the opinion by the clinician \\*Patients may be rescreened after treatment optimization\n* Treatment with digoxin\n* Paget's disease or other metabolic bone disorders\n* Antiresorptive or bone anabolic medication during the last 24 months (for bisphosphonates it is only during the last 12 months)\n* Former or present malignant disease (except skin basal or planocellular carcinoma)\n* Previous external beam or implant radiation therapy to the skeleton\n* Patients who have undergone a kidney transplantation within the last 12 months\n* 25 hydroxyvitamin D2 and D3 \\\u003C50 nmol\u002Fl \\*Patients may be rescreened after correction\n* Inability to administer teriparatide\n* Reduced liver function \\*Alanine Aminotransferase (ALAT) \\>3x upper limit of normal or bilirubin \\> 2x upper limit of normal\n* Pregnancy, lactation or fertile women (post-menopausal females are not considered fertile) not using safe anticonception (the following contraceptive methods are considered appropriate: Intrauterine device (IUD) or hormonal anticontraceptive (oral contraceptives, implant, transdermal patches, vaginal ring or depot injection)).\n* Hypersensitivity to the active substance in teriparatide or to any of the excipients or content\n* Inability to provide informed consent\n* Medical conditions or treatments that may interfere with assessments of the outcomes of the trial\n* Drug or alcohol abuse\n* Unable to participate in a clinical study based on the judgement by the local investigator\n* For those participating in the bone biopsy procedure: 1) Hypersensitivity to any of the tetracyclines or to any of the excipients or content, 2) Treatment with anticoagulants (vitamin K antagonists, Non-vitamin K Antagonist Oral Anticoagulants (NOAC), unfractionated or low-molecular heparin or antiplatelet agents that, due to clinical indication can't be paused, 3) Disturbances in thrombosis and\u002For haemostasis\n* For those participating in pulse wave measurements: 1) Atrial fibrillation, 2) Aorta stenosis","120 Years",{"count":146,"type":22},48,[148],"PHASE4","This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for treatment of adynamic bone disorder in patients with chronic kidney disease.",[151,152,153,154],"Adynamic Bone Disease","Chronic Kidney Diseases","Cardiac Disease","Chronic Kidney Disease-Mineral and Bone Disorder",[156,157],"Fracture risk","Teriparatide","2024-04-19",{"date":160,"type":43},"2024-04-23",{"date":162,"type":43},"2021-12-15",{"date":106,"type":22},{"name":165,"class":50},"Ditte Hansen",4,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":176,"studyType":119,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":189,"locationsCount":51},"100457856","integrated-diagnosis-and-treatment-of-ckd-on-outcomes-100457856","NCT05242055","Integrated Diagnosis and Treatment of CKD on Outcomes","A Prospective, Cohort, and Observational Study of the Effect of Integrated Diagnosis and Treatment of Chronic Kidney Disease (CKD) on Clinical Outcomes in Real World Clinical Practice","Inclusion Criteria:\n\n* ≥18 years old;\n* Voluntarily signed informed consent;\n* Patients who are estimated to develop CKD.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or ≥100 years;\n* Unable to comply with the procedures stipulated in this study;\n* Estimated follow-up time ≤6 months.","100 Years",{"count":117,"type":22},"5 Years","Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical prognosis of patients with different stratification.\n\nMethods: By establishing a cohort of 1000 patients with CKD and conducting long-term follow-up, integrated diagnosis and treatment for CKD was performed, namely: Regular monitoring, control of blood pressure, blood glucose, blood lipid, correction of anemia, minerals - bone metabolic abnormalities, malnutrition, acid and alkali, and electrolyte disorder, diet and exercise, such as the guidance of integrated management, non intrusive, observational studies, prospective cohort were analyzed retrospectively, describe the implementation of the integration of diagnosis and treatment, chronic kidney disease (CKD) Stratified analysis and risk factor analysis were performed for cardiovascular disease and other main endpoint events, so as to objectively reflect the status of integrated treatment of CKD and provide data support for continuous quality improvement of CKD diagnosis and treatment and improvement of clinical prognosis of patients.",[152,29,179,180,181,154,182],"Hyperglycemia","Hyperlipidemias","Anemia","Malnutrition","2022-05-02",{"date":185,"type":43},"2022-05-06",{"date":187,"type":43},"2022-02-01",{"date":80,"type":22},{"name":190,"class":50},"Capital Medical University"]